SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity - Quiz - MDSpire

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

  • By

  • Barbara Pala

  • Mariagrazia Piscione

  • Maria Carmela Di Marcantonio

  • Francesco Cribari

  • Roberta Vitale

  • Thomas Baldi

  • Ada Popolo

  • Gabriella Mincione

  • June 9, 2026

  • 0 min

Share

Original Source(s)

SIMVASTATIN as a potential protective strategy against doxorubicin-induced cardiotoxicity

  • by Barbara Pala, Mariagrazia Piscione, Maria Carmela Di Marcantonio, Francesco Cribari, Roberta Vitale, Thomas Baldi, Ada Popolo, Gabriella Mincione

  • June 9, 2026

Related Content

Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis

Framingham risk score associates with incident cancer and heart failure

Effects of exercise training on nitric oxide metabolites in heart failure with reduced or preserved ejection fraction: a secondary analysis of the SMARTEX-HF and OptimEx-Clin trials